FCIM
IBB icon

Fairview Capital Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

Fairview Capital Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,076
Closed -$214K – 118
2017
Q2 		$214K Hold
2,076
– – 0.01% 107
2017
Q1 		$203K Buy
+2,076
New +$199K 0.01% 98

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fairview Capital Investment Management's IBB Position: Q3 2017 in Review

Fairview Capital Investment Management sold out of iShares Biotechnology ETF (IBB) in Q3 2017, closing a stake of 2,076 shares — an estimated $214K sold.

Fairview Capital Investment Management first reported a position in IBB in Q1 2017 and held it in 2 quarters. The position peaked at $214K in Q2 2017. 584 funds tracked by Wall St. Rank hold IBB as of Q3 2017.

  • Fairview Capital Investment Management reported no remaining iShares Biotechnology ETF position as of Q3 2017 after selling out during the quarter.
  • Fairview Capital Investment Management sold 2,076 iShares Biotechnology ETF shares in Q3 2017, an estimated $214K.
  • Fairview Capital Investment Management first reported a position in iShares Biotechnology ETF in Q1 2017 and held it in 2 quarters.
  • Fairview Capital Investment Management's iShares Biotechnology ETF position peaked at $214K in Q2 2017.
  • 584 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2017.

Based on Fairview Capital Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.